OncoMatch/Clinical Trials/NCT05638295
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
Is NCT05638295 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Panitumumab and Sotorasib for advanced malignant solid neoplasm.
Treatment: Panitumumab · Sotorasib — This phase II ComboMATCH treatment trial tests how well AMG 510 (sotorasib) with or without panitumumab works in treating patients with KRAS G12C mutant solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Sotorasib is in a class of medications called KRAS inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells. Panitumumab is in a class of medications called monoclonal antibodies. It works by slowing or stopping the growth of cancer cells. Giving combination panitumumab and sotorasib may kill more tumor cells in patients with advanced solid tumors with KRAS G12C mutation.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Required: KRAS g12c
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard of care therapy — advanced/metastatic
Patient must have progressed on at least one line of standard of care therapy in the advanced/metastatic setting
Lab requirements
Kidney function
Creatinine <= 1.5 x institutional ULN OR creatinine clearance > 50 mL/min/1.73 m^2 for patients with creatinine levels > 1.5 mg/dL as per Cockcroft-Gault
Liver function
Total bilirubin <= 1.5 x institutional upper limit of normal (ULN); AST/ALT < 3 x institutional ULN
Cardiac function
NYHA class 2B or better
Total bilirubin <= 1.5 x institutional upper limit of normal (ULN)...AST/ALT < 3 x institutional ULN...Creatinine <= 1.5 x institutional ULN OR creatinine clearance > 50 mL/min/1.73 m^2...NYHA class 2B or better
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Regional Cancer Center at Johnson City Medical Center · Johnson City, Tennessee
- Ballad Health Cancer Care - Kingsport · Kingsport, Tennessee
- Wellmont Holston Valley Hospital and Medical Center · Kingsport, Tennessee
- Vanderbilt University/Ingram Cancer Center · Nashville, Tennessee
- Scott and White Memorial Hospital · Temple, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify